Key result
Targeting hnRNP A1 emerges as a promising strategy for cancers and neurodegenerative diseases.
Why the study?
Abnormal RNA metabolism regulated by RNA binding proteins contributes to multiple diseases, and targeting the dysregulated RNA binding protein hnRNP A1 represents a promising therapeutic approach.
This review summarizes the molecular mechanisms of hnRNP A1 in RNA metabolism and alternative splicing, highlighting its potential as a therapeutic target in various diseases.
Answers are grounded in this paper and cite their sources.
Requires rigorous trials before hnRNP A1 drugs; extends preclinical rationale but leaves clinical translation open.
Abnormal RNA metabolism, regulated by various RNA binding proteins, can have functional consequences for multiple diseases. Heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) is an important RNA binding protein, that regulates various RNA metabolic processes, including transcription, alternative splicing of pre-mRNA, translation, miRNA processing and mRNA stability. As a potent splicing factor, hnRNP A1 can regulate multiple splicing events, including itself, collaborating with other cooperative or antagonistical splicing factors by binding to splicing sites and regulatory elements in exons or introns. hnRNP A1 can modulate gene transcription by directly interacting with promoters or indirectly impacting Pol II activities. Moreover, by interacting with the internal ribosome entry site (IRES) or 3'-UTR of mRNAs, hnRNP A1 can affect mRNA translation. hnRNP A1 can alter the stability of mRNAs by binding to specific locations of 3'-UTR, miRNAs biogenesis and Nonsense-mediated mRNA decay (NMD) pathway. In this review, we conclude the selective sites where hnRNP A1 binds to RNA and DNA, and the co-regulatory factors that interact with hnRNP A1. Given the dysregulation of hnRNP A1 in diverse diseases, especially in cancers and neurodegeneration diseases, targeting hnRNP A1 for therapeutic treatment is extremely promising. Therefore, this review also provides the small-molecule drugs, biomedicines and novel strategies targeting hnRNP A1 for therapeutic purposes.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2022) conducted a review in Cancers and neurodegenerative diseases. hnRNP A1 targeted therapies was evaluated. Targeting hnRNP A1 with small-molecule drugs and biomedicines is a promising therapeutic strategy for cancers and neurodegenerative diseases driven by abnormal RNA metabolism.
Synapse has enriched 10 related papers. Consider them for comparative context: